A carregar...
DIPG-25. GENETIC ALTERATIONS TARGETING THE MAPK PATHWAY CONFERS PRECLINICAL SENSITIVITY TO TRAMETINIB IN A CO-CLINICAL TRIAL IN DIPG
The survival of children with DIPG remains dismal, and new treatments are desperately needed. The development of patient-specific in vitro and in vivo models represents one such opportunity, however the time taken to establish such models and the rapid disease progression has been thought to limit t...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6477199/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.046 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|